Microalbuminuria was associated with an increased risk of death and cardiovascular disease to a similar extent as the metabolic syndrome (RR ~2; P<0.001).
Observational (n=2,696)
Do microalbuminuria and metabolic syndrome increase the risk of cardiovascular disease and mortality in the general population?
Microalbuminuria confers an increased risk of death and cardiovascular disease to a similar extent as the metabolic syndrome in the general population.
Relative Risk: 2
p-value: p=< 0.001
OBJECTIVE: Microalbuminuria and metabolic syndrome are both associated with cardiovascular disease (CVD). The aim of this study was to determine the potential association between numbers of components in the metabolic syndrome, different levels of microalbuminuria and renal function. We also aimed to determine the risk of death and CVD at different levels of microalbuminuria and renal function and numbers of components in the metabolic syndrome. DESIGN: Population-based observational follow-up study. SETTING: Epidemiological research unit (Copenhagen City Heart Study). SUBJECTS: A total of 2,696 men and women, 30-70 years of age. BASELINE MEASURES: Urinary albumin excretion (UAE), creatinine clearance and metabolic risk factors were measured in 1992-1994. MAIN OUTCOME MEASUREMENTS: The participants were followed prospectively by registers until 1999-2000 with respect to CVD, and until 2004 with respect to death. RESULTS: We found a strong association between microalbuminuria and the metabolic syndrome: 2% with none and 18% with five metabolic risk factors had microalbuminuria (P 5 microg min(-1)) confers increased risk of death and CVD to a similar extent as the metabolic syndrome.
Klausen et al. (2007) conducted an observational in General population (n=2,696). Microalbuminuria vs. Absence of microalbuminuria was evaluated on Death and cardiovascular disease (RR 2, p=< 0.001). Microalbuminuria was associated with an increased risk of death and cardiovascular disease to a similar extent as the metabolic syndrome (RR ~2; P<0.001).